Arcellx Inc Revenue Growth Rates (ACLX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Arcellx Inc   (NASDAQ: ACLX)
 

ACLX's Revenue Growth by Quarter and Year

Arcellx Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ACLX Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 1.65
3rd Quarter September 4.95
2nd Quarter June 7.55
1st Quarter March 8.13
FY 22.28





ACLX Revenue fourth quarter 2025 Y/Y Growth Comment
Arcellx Inc reported drop in Revenue in the fourth quarter 2025 by -89.17% to $ 1.65 millions, from the same quarter in 2024.
This represents worst decline in recent Company history.

Looking into fourth quarter 2025 results within Biotechnology & Pharmaceuticals industry 79 other companies have achieved higher Revenue growth. While Arcellx Inc ' s Revenue meltdown of -89.17% ranks overall at the positon no. 4352 in the fourth quarter 2025.


ACLX Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December -89.17 % -75.82 % - -
3rd Quarter September -80.98 % 74 % - -
2nd Quarter June -72.43 % 91.47 % - -
1st Quarter March -79.29 % 119.21 % - -
FY   -79.36 % -2.16 % - -

Financial Statements
Arcellx Inc 's fourth quarter 2025 Revenue $ 1.65 millions ACLX's Income Statement
Arcellx Inc 's fourth quarter 2024 Revenue $ 15.27 millions Quarterly ACLX's Income Statement


ACLX Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December -66.59 % -41.34 % 322.13 % -
3rd Quarter September -34.44 % -4.93 % 4.62 % -
2nd Quarter June -7.13 % -30.26 % -20.16 % -
1st Quarter March -46.76 % -37.83 % - -
FY (Year on Year)   -79.36 % -2.16 % - -


Back to ACLX Growth rate Comparisons >> Back to ACLX Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #80
Healthcare Sector #613
Overall #4352

Revenue Y/Y Growth Statistics
High Average Low
119.16 % -14.13 % -89.17 %
(Dec 31 2024)   (Dec 31 2025)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #80
Healthcare Sector #613
Overall #4352
Revenue Y/Y Growth Statistics
High Average Low
119.16 % -14.13 % -89.17 %
(Dec 31 2024)   (Dec 31 2025)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Arcellx Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
322.2 % 3.4 % -66.58 %
(Dec 31 2023)  


ACLX's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2025 Arcellx Inc disclosed fall in Revenue from the third quarter by -66.59% to $ 1.65 millions, from $ 4.95 millions achived in the previous reporting period.

But that's not important problem, as Arcellx Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 30 other companies have achieved higher Revenue quarter on quarter growth. While Arcellx Inc 's Revenue growth quarter on quarter, overall rank is 2070.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #31
Healthcare Sector #256
Overall #2070
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #31
Healthcare Sector #256
Overall #2070
Revenue Q/Q Growth Statistics
High Average Low
322.2 % 3.4 % -66.58 %
(Dec 31 2023)  


ACLX's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2025 Arcellx Inc disclosed fall in Revenue from the third quarter by -66.59% to $ 1.65 millions, from $ 4.95 millions achived in the previous reporting period.

But that's not important problem, as Arcellx Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 30 other companies have achieved higher Revenue quarter on quarter growth. While Arcellx Inc 's Revenue growth quarter on quarter, overall rank is 2070.


Arcellx Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)
Cumulative Revenue 12 Months Ending $ 22.29 $ 35.90 $ 56.98 $ 76.81 $ 107.94
Y / Y Revenue Growth (TTM) -79.35 % -76.96 % -60.63 % -41.66 % -2.16 %
Year on Year Revenue Growth Overall Ranking # 1994 # 1722 # 2052 # 1891 # 1470
Seqeuential Revenue Change (TTM) -37.92 % -37 % -25.82 % -28.84 % -30.73 %
Seq. Revenue Growth (TTM) Overall Ranking # 2504 # 958 # 1089 # 496 # 427


Cumulative Revenue growth Comment
Arcellx Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -79.35% year on year, at Dec 31 2025 compare to the -76.96% decrease at Sep 30 2025. If the Arcellx Inc 's fiscal year would end at Dec 31 2025, annual Revenue would be $22 millions.

In the Healthcare sector 278 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1722 to 1994.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 32
Healthcare Sector # 279
Overall # 1994

Revenue TTM Y/Y Growth Statistics
High Average Low
-2.16 %
 -52.15 %
-79.35 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 32
Sector # 324
S&P 500 # 2504
Cumulative Revenue growth Comment
Arcellx Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -79.35% year on year, at Dec 31 2025 compare to the -76.96% decrease at Sep 30 2025. If the Arcellx Inc 's fiscal year would end at Dec 31 2025, annual Revenue would be $22 millions.

In the Healthcare sector 278 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1722 to 1994.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 32
Healthcare Sector # 279
Overall # 1994

Revenue TTM Y/Y Growth Statistics
High Average Low
-2.16 %
-52.15 %
-79.35 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 32
Sector # 324
S&P 500 # 2504




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ACLX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Ardent Health Inc -0.08%$ -0.075 millions
Chemed Corporation-0.10%$ -0.103 millions
Embecta Corp -0.15%$ -0.153 millions
Bruker Corporation-0.24%$ -0.245 millions
Vaso Corporation-0.38%$ -0.376 millions
Bio techne Corp-0.54%$ -0.542 millions
Lftd Partners Inc -0.76%$ -0.763 millions
Xtant Medical Holdings Inc -0.82%$ -0.821 millions
Charles River Laboratories International inc -0.83%$ -0.830 millions
Koninklijke Philips Nv-1.04%$ -1.038 millions
Evotec Se-1.08%$ -1.078 millions
Pfizer Inc-1.16%$ -1.160 millions
Adapthealth Corp -1.21%$ -1.209 millions
Avantor Inc -1.36%$ -1.364 millions
Alpha Teknova Inc -1.42%$ -1.422 millions
Skinhealth Systems Inc -1.57%$ -1.569 millions
Pediatrix Medical Group Inc -1.71%$ -1.711 millions
Integra Lifesciences Holdings Corp-1.74%$ -1.744 millions
Edap Tms Sa-1.78%$ -1.783 millions
Vivos Therapeutics Inc -2.18%$ -2.178 millions
Absci Corp-2.26%$ -2.256 millions
Prestige Consumer Healthcare Inc -2.30%$ -2.303 millions
Perrigo Company Plc-2.52%$ -2.521 millions
Bionano Genomics Inc -2.60%$ -2.597 millions
Haemonetics Corporation-2.64%$ -2.636 millions
Amphastar Pharmaceuticals Inc -2.79%$ -2.790 millions
Strata Skin Sciences Inc-2.97%$ -2.966 millions
Plus Therapeutics Inc -3.19%$ -3.187 millions
Harvard Bioscience Inc -3.23%$ -3.226 millions
Brookdale Senior Living Inc -3.44%$ -3.439 millions


About Arcellx Inc Revenue Growth Rates (ACLX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Arcellx Inc (CIK 1786205).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-076876
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Arcellx Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.